Information  X 
Enter a valid email address

Henderson Morley PLC (HML)

  Print      Mail a friend

Monday 02 March, 2009

Henderson Morley PLC

Koi Herpes Vaccine Update

RNS Number : 0546O
Henderson Morley PLC
02 March 2009
 

2 March 2009

 

HENDERSON MORLEY PLC

(AIM: HML)

('Henderson Morley' or 'the Company')

 

Koi Herpes Vaccine update

 

Henderson Morley plc, the AIM quoted biotechnology company, is pleased to announce the commencement of the next phase of studies to examine the efficacy of the Koi Herpes Vaccine candidates. The studies will be examining several advanced formulations of vaccine, which include several new adjuvant candidates (compounds added to the vaccine to improve immune responses). 

 

The studies, which are being completed by a sub-contract facility, will be examining three different vaccine formulations, and a combination of five different adjuvants, making ten study groups in total. 

 

The serological studies that are a crucial and important part of the vaccine development process (to enable assessment of immune responses) have been further optimised and validated to support the study. 

 

It is anticipated that the results of this study will be available by July 2009, and the results will be submitted to Schering Plough Animal health under the terms of the collaborative research and option agreement.

 

 

 

---ENDS---

 

 

ENQUIRIES:

 

HENDERSON MORLEY PLC                                                            0121 442 4600

Andrew Knight, Chairman            

BISHOPSGATE COMMUNICATIONS LTD                                    0207 562 3350
(Public Relations)
              
Maxine Barnes
Nick Rome


BREWIN DOLPHIN INVESTMENT BANKING
                                0113 241 0126

(Nominated Adviser)

Neil Baldwin

 

HYBRIDAN LLP                                                                                    0203 159 5085

(Broker)  

Claire Noyce/Stephen Austin    

 

 

 

Notes to Editors:

 

Henderson Morley was founded in 1996 with the objective of developing its anti viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platform and has been developed in-house and HML wholly owns the patent IPR. 

 

Further information on Henderson Morley plc can be accessed through the Company's website at www.henderson-morley.com

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STREDLFLKLBEBBD

a d v e r t i s e m e n t